Innowacja lekowa w świetle ustawy refundacyjnej

• Authors: Bochenek Tomasz

Title variants

EN

The pharmaceutical innovation and the reimbursed act

• Languages of publication: PL

Abstracts

EN

The innovation in pharmaceutical sector can be characterized as incremental. The expectations towards new drugs are very high but the access of Polish patients to the pharmaceutical innovation is limited. Role and perception of this innovation within the Polish health care policy are not signaled coherently and unambiguously. The Reimbursement Act is an important new legal act, which was intensely debated in the second half of 2010 and the first half of 2011.This legal act changes conditions of functioning of virtually all subjects acting on the market of pharmaceuticals which are financed from public sources. The Reimbursement Act introduces thorough changes into the pharmaceutical policy and pricing and reimbursement policies. These changes can influence the pharmaceutical innovation in the Polish health care system. It is impossible to circumscribe the direction of these changes decisively. However, there is a hope for a summary positive influence of new regulations, so monitoring of a manner of implementation of the Reimbursement Act will be necessary.

Keywords

EN

PAY-BACK; PHARMACEUTICAL INNOVATION; PHARMACEUTICAL POLICY; PHARMACEUTICAL PRICING; PHARMACEUTICAL REIMBURSEMENT; RISK-SHARING

• Publisher: Uniwersytet Jagielloński
• Journal: Zdrowie Publiczne i Zarządzanie
• Year: 2010
• Volume: 8
• Issue: 2
• Pages: 87-95
• Document type: ARTICLE

Contributors

author

Bochenek Tomasz

• Zaklad Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydzial Nauk o Zdrowiu, CM UJ, ul. Grzegorzecka 20, Krakow, Poland

Identifiers

CEJSH db identifier

11PLAAAA10237